PL376557A1 - Postacie krystaliczne pitawastatyny wapnia - Google Patents
Postacie krystaliczne pitawastatyny wapniaInfo
- Publication number
- PL376557A1 PL376557A1 PL376557A PL37655704A PL376557A1 PL 376557 A1 PL376557 A1 PL 376557A1 PL 376557 A PL376557 A PL 376557A PL 37655704 A PL37655704 A PL 37655704A PL 376557 A1 PL376557 A1 PL 376557A1
- Authority
- PL
- Poland
- Prior art keywords
- crystalline forms
- pitavastatin calcium
- pitavastatin
- calcium
- quinolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03405080 | 2003-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL376557A1 true PL376557A1 (pl) | 2006-01-09 |
Family
ID=32865094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL376557A PL376557A1 (pl) | 2003-02-12 | 2004-02-02 | Postacie krystaliczne pitawastatyny wapnia |
Country Status (10)
Country | Link |
---|---|
US (15) | US20060142582A1 (pl) |
EP (3) | EP1592668A1 (pl) |
JP (13) | JP5192147B2 (pl) |
CN (3) | CN102285916B (pl) |
AU (1) | AU2004212160B2 (pl) |
CA (2) | CA2785954A1 (pl) |
DE (1) | DE202004021379U1 (pl) |
PL (1) | PL376557A1 (pl) |
TW (4) | TWI485135B (pl) |
WO (1) | WO2004072040A1 (pl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202004021379U1 (de) * | 2003-02-12 | 2008-02-21 | Ciba Specialty Chemicals Holding Inc. | Kristalline Formen von Pitivastatin Calcium |
TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
AU2013204129C1 (en) * | 2003-12-26 | 2017-03-02 | Nissan Chemical Industries, Ltd. | Crystal Form of Quinoline Compound and Process for its Production |
EP1711493A2 (en) * | 2004-02-06 | 2006-10-18 | CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement | Crystalline forms of zolmitriptan |
CA2594692A1 (en) * | 2005-01-31 | 2006-08-03 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of rosuvastatin calcium salt |
JP2013516459A (ja) | 2010-01-20 | 2013-05-13 | カディラ・ヘルスケア・リミテッド | ピタバスタチン及び医薬として許容可能なそれらの塩の製造方法 |
JP2013536219A (ja) | 2010-08-25 | 2013-09-19 | カディラ・ヘルスケア・リミテッド | ピタバスタチンカルシウムおよびその調製方法 |
WO2012063254A1 (en) * | 2010-11-12 | 2012-05-18 | Hetero Research Foundation | Novel polymorphs of pitavastatin calcium |
WO2012106584A2 (en) * | 2011-02-04 | 2012-08-09 | Dr. Reddy's Laboratories Ltd. | Pitavastatin salts |
ITMI20111475A1 (it) * | 2011-08-02 | 2013-02-03 | Dipharma Francis Srl | Forme cristalline di pitavastatina sale di calcio |
ES2620968T3 (es) | 2011-09-12 | 2017-06-30 | Farma Grs, D.O.O. | Forma polimórfica de pitavastatina cálcica |
KR102139537B1 (ko) * | 2011-10-20 | 2020-07-31 | 오리존 지노믹스 에스.에이. | Lsd1 억제제로서 (헤테로)아릴 사이클로프로필아민 화합물 |
WO2013098773A1 (en) * | 2011-12-28 | 2013-07-04 | Dr. Reddy's Laboratories Limited | Crystalline forms of pitavastatin calcium |
CN104844506A (zh) * | 2015-05-15 | 2015-08-19 | 苗怡文 | 一种治疗高血脂症的药物匹伐他汀钙化合物 |
CN104860882A (zh) * | 2015-05-15 | 2015-08-26 | 苗怡文 | 一种治疗高血脂症的药物匹伐他汀钙组合物 |
CN105213319A (zh) * | 2015-09-17 | 2016-01-06 | 青岛华之草医药科技有限公司 | 一种降血脂药物匹伐他汀钙组合物干混悬剂 |
CN105125504A (zh) * | 2015-09-17 | 2015-12-09 | 青岛华之草医药科技有限公司 | 一种降血脂药物匹伐他汀钙组合物颗粒剂 |
US10937978B2 (en) * | 2016-02-25 | 2021-03-02 | University Of Louisville Research Foundation, Inc. | Methods for forming a perovskite solar cell |
US10600502B2 (en) | 2016-12-20 | 2020-03-24 | Astrazeneca Uk Ltd. | Systems and methods for dispensing a statin medication over the counter |
CN109053568A (zh) * | 2018-08-29 | 2018-12-21 | 南京卓康医药科技有限公司 | 一种高纯度匹伐他汀钙新晶型及其制备方法 |
CN113834795A (zh) * | 2020-06-08 | 2021-12-24 | 上海医药集团股份有限公司 | 硫酸羟氯喹颗粒水分近红外光谱在线定量模型及其建立方法及检测方法 |
US20220008519A1 (en) | 2020-07-09 | 2022-01-13 | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) | Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho |
WO2023049312A1 (en) * | 2021-09-23 | 2023-03-30 | Erasca, Inc. | Egfr inhibitor polymorph forms |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3175944A (en) * | 1956-06-18 | 1965-03-30 | Upjohn Co | Dihydronovobiocin and derivatives thereof |
JPS61171460A (ja) | 1985-01-23 | 1986-08-02 | Dainippon Pharmaceut Co Ltd | 塩酸メクロフエノキサ−ト1型結晶の製造法 |
CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
GB8816620D0 (en) * | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
JP3528186B2 (ja) | 1991-06-24 | 2004-05-17 | 日産化学工業株式会社 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
JP2575590B2 (ja) | 1992-07-31 | 1997-01-29 | 塩野義製薬株式会社 | トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法 |
ES2115725T3 (es) | 1992-07-31 | 1998-07-01 | Shionogi & Co | Hidrocloruro de triazoliltiometiltiocefalosporina, su hidrato cristalino y la preparacion de este. |
GB9324931D0 (en) * | 1993-12-04 | 1994-01-26 | Pfizer Ltd | Glutaramide derivatives |
CN1136183C (zh) | 1994-02-25 | 2004-01-28 | 代科化学工业株式会社 | 光学活性甲羟戊酸内酯类化合物的制造方法 |
JP3558684B2 (ja) | 1994-06-28 | 2004-08-25 | 塩野義製薬株式会社 | ピロリジルチオカルバペネム誘導体の乾燥方法 |
NZ509401A (en) * | 1998-07-23 | 2002-08-28 | Nissan Chemical Ind Ltd | Process for the preparation of quinoline derivative using the intermediate 2-cyclopropyl-3-(3-cyano-prop-2-ene)-4-(4-fluorophenyl)-quinoline |
JP4749533B2 (ja) * | 1999-09-30 | 2011-08-17 | 大塚化学株式会社 | セファロスポリン結晶 |
EP1330427A1 (en) * | 2000-10-31 | 2003-07-30 | Ciba SC Holding AG | Crystalline forms of venlafaxine hydrochloride |
MXPA03004276A (es) * | 2000-11-16 | 2005-04-29 | Teva Pharma | Hidrolisis de esteres del acido (r(r*, r*)-2 -(4-fluorofenil)- beta, delta- dihidroxi-5 -(1-metiletil)- 3-fenil-4 -((fenilamino) carbonil)- 1h-pirrol-1 -heptanoico con hidroxido de calcio. |
EP1345903A1 (en) * | 2000-12-21 | 2003-09-24 | Ciba SC Holding AG | Crystalline forms of cerivastatin sodium |
EP1425287A4 (en) * | 2001-08-16 | 2005-09-07 | Teva Pharma | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINES |
US6835838B2 (en) | 2002-01-28 | 2004-12-28 | Novartis Ag | Process for the manufacture of organic compounds |
PL370658A1 (pl) | 2002-01-31 | 2005-05-30 | Novartis Ag | Sposób wytwarzania inhibitorów reduktazy HMG-CoA |
GB0204129D0 (en) | 2002-02-21 | 2002-04-10 | Novartis Ag | Process for the manufacture of organic compounds |
WO2003087091A1 (fr) | 2002-04-17 | 2003-10-23 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau cristal d'anhydride de derive de quinoxalinedione |
GB0210234D0 (en) | 2002-05-03 | 2002-06-12 | Novartis Ag | Process for the manufacture of organic compounds |
DE202004021379U1 (de) * | 2003-02-12 | 2008-02-21 | Ciba Specialty Chemicals Holding Inc. | Kristalline Formen von Pitivastatin Calcium |
TWI328006B (en) | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
CN100344422C (zh) * | 2006-05-11 | 2007-10-24 | 朱能国 | 用人工用材林松木及其板材生产阻燃防潮装饰板材的方法 |
JP5353678B2 (ja) * | 2009-12-17 | 2013-11-27 | トヨタ自動車株式会社 | 車両の制御装置 |
-
2004
- 2004-02-02 DE DE202004021379U patent/DE202004021379U1/de not_active Expired - Lifetime
- 2004-02-02 CA CA2785954A patent/CA2785954A1/en not_active Abandoned
- 2004-02-02 CN CN201110189197.4A patent/CN102285916B/zh not_active Expired - Lifetime
- 2004-02-02 JP JP2006501997A patent/JP5192147B2/ja not_active Expired - Lifetime
- 2004-02-02 EP EP04707232A patent/EP1592668A1/en not_active Withdrawn
- 2004-02-02 EP EP12001247A patent/EP2500339A1/en not_active Withdrawn
- 2004-02-02 AU AU2004212160A patent/AU2004212160B2/en not_active Expired
- 2004-02-02 WO PCT/EP2004/050066 patent/WO2004072040A1/en active Application Filing
- 2004-02-02 US US10/544,752 patent/US20060142582A1/en not_active Abandoned
- 2004-02-02 EP EP17200172.9A patent/EP3299359A1/en not_active Withdrawn
- 2004-02-02 PL PL376557A patent/PL376557A1/pl unknown
- 2004-02-02 CN CN2008100012910A patent/CN101219992B/zh not_active Expired - Lifetime
- 2004-02-02 CN CNB2004800039523A patent/CN100374422C/zh not_active Expired - Lifetime
- 2004-02-02 CA CA002513837A patent/CA2513837A1/en not_active Abandoned
- 2004-02-10 TW TW102126646A patent/TWI485135B/zh not_active IP Right Cessation
- 2004-02-10 TW TW100127719A patent/TW201213311A/zh unknown
- 2004-02-10 TW TW093103012A patent/TW200420541A/zh unknown
- 2004-02-10 TW TW103129170A patent/TW201514149A/zh unknown
-
2008
- 2008-12-09 US US12/331,086 patent/US20090182008A1/en not_active Abandoned
-
2011
- 2011-06-07 JP JP2011127696A patent/JP2011201915A/ja not_active Withdrawn
- 2011-10-25 US US13/280,431 patent/US20120101126A1/en not_active Abandoned
-
2012
- 2012-10-31 US US13/664,498 patent/US8557993B2/en not_active Expired - Lifetime
-
2013
- 2013-06-25 JP JP2013132593A patent/JP5366163B2/ja not_active Expired - Lifetime
- 2013-09-03 US US14/016,399 patent/US8853405B2/en not_active Expired - Lifetime
- 2013-09-03 JP JP2013182394A patent/JP5445713B2/ja not_active Expired - Lifetime
- 2013-12-06 JP JP2013253095A patent/JP5500305B2/ja not_active Expired - Lifetime
- 2013-12-20 JP JP2013264348A patent/JP2014055185A/ja not_active Withdrawn
-
2014
- 2014-07-30 JP JP2014155001A patent/JP5702494B2/ja not_active Expired - Lifetime
- 2014-08-05 JP JP2014159459A patent/JP2014205723A/ja not_active Withdrawn
- 2014-08-26 US US14/468,572 patent/US20140364614A1/en not_active Abandoned
-
2015
- 2015-07-06 JP JP2015135320A patent/JP2015172086A/ja not_active Withdrawn
- 2015-10-01 US US14/872,255 patent/US20160024010A1/en not_active Abandoned
-
2016
- 2016-10-04 US US15/284,561 patent/US20170022163A1/en not_active Abandoned
- 2016-10-05 JP JP2016197459A patent/JP2016222737A/ja not_active Withdrawn
-
2017
- 2017-10-05 US US15/725,397 patent/US20180029987A1/en not_active Abandoned
- 2017-12-20 JP JP2017244040A patent/JP2018044009A/ja not_active Withdrawn
-
2018
- 2018-08-03 US US16/053,879 patent/US20180346425A1/en not_active Abandoned
- 2018-11-29 JP JP2018223591A patent/JP2019031574A/ja active Pending
-
2019
- 2019-05-01 US US16/400,566 patent/US20190256469A1/en not_active Abandoned
-
2020
- 2020-01-13 US US16/740,516 patent/US20200148644A1/en not_active Abandoned
- 2020-06-30 JP JP2020113164A patent/JP2020169196A/ja active Pending
- 2020-09-23 US US17/029,692 patent/US20210002227A1/en not_active Abandoned
-
2022
- 2022-02-18 US US17/675,413 patent/US20220169614A1/en not_active Abandoned
-
2023
- 2023-06-16 US US18/336,332 patent/US20230322680A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL376557A1 (pl) | Postacie krystaliczne pitawastatyny wapnia | |
TW200631944A (en) | Potassium salt of an HIV integrase inhibitor | |
SI1263739T1 (sl) | Kristalinicne soli (E)-7-(4-(4-fluorofenil)-6-izopril-2- (metil(metilsulfonil)amino)pirimidin-5-il)-(3R,5S)-3,5-dihidroksihept- 6-enojske kisline | |
CY1109173T1 (el) | Κρυσταλλικη μορφη του δις [(ε)-7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2-[μεθυλ(μεθυλσουλφονυλ)αμινο]πυριμιδιν-5-υλ](3r,5s)-3,5-διϋδροξυεπτ-6-ενοϊκο οξυ] αλατος ασβεστιου | |
WO2005046589A3 (en) | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties | |
NZ700778A (en) | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof. | |
IS8478A (is) | Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess | |
WO2007070173A3 (en) | Cetp inhibitors | |
TWI341310B (en) | Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt | |
RS51445B (en) | PYROLIDINDION SUBSTITUTED BY PIPERIDINE-PTHALAZONE AS PDE4 INHIBITORS | |
WO2007057225A3 (en) | Process for making montelukast and intermediates therefor | |
EP1978960A4 (en) | USE OF 6- (3-CHLORO-2-FLUORBENZYL) -1 - [(2S) -1-HYDROXY-3-METHYLBUTAN-2-YL [-7-METHOXY-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXYLIC ACID OR SALT THEREOF FOR THE TREATMENT OF RETROVIRUS INFECTION | |
EA200400414A1 (ru) | Кристаллические гидраты производных анилида никотиновой кислоты | |
AU2003209043A1 (en) | Novel anhydrous amorphous forms of montelukast sodium salt | |
MY148393A (en) | Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | |
PE20060767A1 (es) | Derivados de tetrahidroquinolina como inhibidores de cept | |
WO2006064269A3 (en) | Salts of leukotriene antagonist montelukast | |
UA91549C2 (ru) | Производные хинолина как антибактериальные агенты | |
AU2003230831A1 (en) | ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-l, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN) | |
IL189879A0 (en) | Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1h-[naphthyridin-2-one | |
WO2004091278A3 (en) | Gabapentin compositions | |
TW200716101A (en) | 7-fluoro-1, 3-dihydro-indol-2-one oxazolidinones as antibacterial agents | |
AU2001230525A1 (en) | Sulfate salt of quinolonecarboxylic acid derivative and use thereof | |
NZ602758A (en) | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |